Table 3.
Guideline comparison summary table
| Medical condition category | Number of indications | ||||
|---|---|---|---|---|---|
| Ontario | Prairie | Atlantic | British columbia | Québec | |
| Dermatology | N = 2a | N = 16 | N = 16 | N = 1 | N = 15 |
|
Recommended: 1 (50%) Not recommended for routine use: 1 (50%) |
Do: 4 (25%) Do not do: 0 Do not know: 12 (75%) |
Indicated conditions: 4(25%) Possibly indicated conditions: 12(75%) |
Approved/Recommended: 1 (100%) Not recommended: 0 |
Recommended: 2 (13%) Possible option: 7 (47%) Not recommended: 4 (27%) Insufficient data: 2 (13%) |
|
| Hematology | N = 14 | N = 22 | N = 16 | N = 5 | N = 23 |
|
Recommended: 5 (36%) Not recommended for routine use: 9 (64%) |
Do: 12 (55%) Do not do: 3 (14%) Do not know: 7 (32%) |
Indicated conditions: 9 (56%) Possibly indicated conditions: 7 (44%) |
Approved/Recommended: 4 (80%) Not recommended: 1 (20%) |
Recommended: 5 (22%) Possible option: 9 (39%) Not recommended: 7 (30%) Insufficient data: 2 (9%) |
|
| Immunology | N = 2a | N = 2 | N = 5 | N = 2 | N = 42 |
|
Recommended: 2 (100%) Not recommended for routine use: 0 |
Do: 2 (100%) Do not do: 0 Do not know: 0 |
Indicated conditions: 4 (80%) Possibly indicated conditions: 1 (20%) |
Approved/Recommended: 2 (100%) Not recommended: 0 |
Recommended: 11 (26%) Possible option: 11 (26%) Not recommended: 11 (26%) Insufficient data: 9 (21%) |
|
| Infectious Disease | N = 2 | N = 11 | N = 4 | N = 3 | N = 13 |
|
Recommended: 2 (100%) Not recommended for routine use: 0 |
Do: 4 (36%) Do not do: 6 (55%) Do not know: 1 (9%) |
Indicated conditions: 2 (50%) Possibly indicated conditions: 2 (50%) |
Approved/Recommended: 3 (100%) Not recommended: 0 |
Recommended: 0 Possible option: 3 (23%) Not recommended: 7 (54%) Insufficient data: 3 (23%) |
|
| Transplant Medicine | N = 4 | N = 21 | N = 3 | N = 0 | N = 11 |
|
Recommended: 4 (100%) Not recommended for routine use: 0 |
Do: 6 (28%) Do not do: 9 (43%) Do not know: 6 (28%) |
Indicated conditions: 1 (33%) Possibly indicated conditions: 2 (67%) |
Recommended: 0 Possible option: 5 (45%) Not recommended: 2 (18%) Insufficient data: 4 (36%) |
||
| Neurology | N = 10 | N = 49 | N = 19 | N = 12 | N = 27 |
|
Recommended: 4 (40%) Not recommended for routine use: 6 (60%) |
Do: 15 (31%) Do not do: 16 (32%) Do not know: 18 (37%) |
Indicated conditions: 6 (32%) Possibly indicated conditions: 13 (68%) |
Approved/Recommended: 4 (33%) Not recommended: 8 (67%) |
Recommended: 4 (15%) Possible option: 9 (33%) Not recommended: 9 (33%) Insufficient data: 5 (19%) |
|
| Rheumatology | N = 3 | N = 22 | N = 11 | N = 2 | N = 34 |
|
Recommended: 3 (100%) Not recommended for routine use: 0 |
Do: 8 (36%) Do not do: 4 (19%) Do not know: 10 (45%) |
Indicated conditions: 4 (36%) Possibly indicated conditions: 7 (64%) |
Approved/Recommended: 2 (100%) Not recommended: 0 |
Recommended: 1 (3%) Possible option: 12 (35%) Not recommended: 11 (32%) Insufficient data: 10 (29%) |
|
| Total | N = 37 | N = 143 | N = 74 | N = 25 | N = 165 |
|
Level 1: Total recommended: 21 (57%) Level 2: Total not recommended for routine use: 16 (43%) |
Level 1: Total do: 51 (36%) Level 3: Total do not do: 38 (26%) Level 4: Total do not know: 54 (38%) |
Level 1: Total indicated conditions: 30 (41%) Level 2: Total possibly indicated conditions: 44 (59%) |
Level 1: Total Approved/recommended: 16 (64%) Level 3: Total not recommended: 9 (36%) |
Level 1: Total recommended: 23 (14%) Level 2: Total possible option: 56 (34%) Level 3: Total not recommended: 51 (31%) Level 4: Total insufficient data: 35 (21%) |
|
The specific medical conditions under each category can be found in Additional file 1: Table S5
aMedical conditions in the Ontario guideline considered further grouping where toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) were grouped in dermatology, and primary immune deficiency (PID) and secondary immune deficiency (SID) were grouped in immunology